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In order to elucidate the role of the mitogen-activated protein kinases, including JNK, p38 MAPK and ERK, as well as the survival-associated
PI3K/Akt signaling pathway, in the response to chemotherapy, we have conducted a comparative study regarding the effects of doxorubicin on
these pathways. Doxorubicin was determined to elicit the apoptosis of NIH3T3 cells in a dose-dependent manner. Prior to cell death, both Akt and
p38 MAPK were transiently activated, and subsequently inactivated almost wholly, whereas ERK and JNK evidenced sustained activations in
response to the drug treatment. The inhibition of PI3K/Akt and p38 MAPK both accelerated and enhanced doxorubicin-induced apoptosis and
ERK inhibition apparently exerted negative effect on apoptosis. The modulation of PI3K/Akt activation by treatment of LY294002 or expression
of Akt mutants such as Akt-DN or Myr-Akt exerted a significant effect on the activation of ERK1/2. We also observed that PI3K/Akt and
sustained ERK activation were associated intimately with the etoposide-induced apoptosis. Taken together, our results clearly suggest that the
differential regulation of the PI3K/Akt, ERK1/2, and p38 MAPK signaling pathways are crucial in the context of DNA-damaging drug-induced
apoptosis, and this has compelled us to propose that the sustained activation of ERK1/2 pathway may be generally involved in the apoptosis
induced by anticancer DNA-damaging drugs, including doxorubicin and etoposide.
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Anticancer drugs exert their effects by inducing apoptosis in
tumor cells via mitochondrial and death receptor pathways [1].
The specific apoptosis-related or survival-associated pathways
inherent to the effects of an anticancer drug must be thoroughly
characterized to improve benefits of chemotherapy. Despite of
the many reports regarding DNA-damaging drug-mediatedAbbreviations:MAPK, mitogen-activated protein kinase; PARP, poly(ADP-
ribose) polymerase; ERK, extracellular signal-regulated kinase; JNK, c-Jun
NH2-terminal kinase; DAPI, 4′-6′-diamidino-2-phenylindole; DMEM, Dulbec-
co's modified Eagle's Medium; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyl tetrazolium bromide; PKB, protein kinase B; FACS, fluorescence activated
cell sorting
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doi:10.1016/j.bbamcr.2006.06.006chemotherapy, it appears that a more straightforward study will
be required in order to unravel in detail the molecular
mechanisms underlying its apoptotic effects. Doxorubicin is a
quinone-containing anthracycline antibiotic agent, which is
generated by the fungus Streptomyces peucetius. Doxorubicin
has been employed in the treatment of a variety of cancers, and
inflicts DNA damage via the intercalation of the anthracycline
portion, metal ion chelation, or by virtue of free radical
generation. The quinone moiety of anthracycline has been
determined to function as a catalyst in the formation of reactive
oxygen species (ROS), including the superoxide anion and
hydrogen peroxide [2]. As much as 60% of the total amount of
intracellular doxorubicin has been determined to be localized in
the nucleus, thereby indicating that members of the anthracy-
cline family, most notably doxorubicin, have a high degree of
affinity for the nuclei of cells. They have also been shown to
intercalate with the DNA, and to partially uncoil the double-
stranded helix. The binding of doxorubicin to DNA has been
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and nucleic acid synthesis. Similarly to etoposide, another
plant-derived DNA-damaging antitumor drug, doxorubicin has
also been observed to inhibit DNA topoisomerase II, which is
critical for the proper functioning of DNA. These anthracycline-
induced perturbations of cellular DNA are believed to culminate
in a final common endonucleolytic DNA fragmentation
pathway, also known as apoptosis. Although a variety of
previous studies have indicated that several survival-related or
death-associated signaling pathways, including the PI3K/Akt
and MAPKs pathways, play pivotal roles in the regulation of
DNA damage-induced apoptosis, the exact molecular mechan-
isms responsible for doxorubicin-induced apoptosis have yet
to be elucidated in detail [3,4]. Moreover, the results of
studies concerning anti-cancer drug-induced apoptosis have
been somewhat controversial, and only a very limited amount
of information is available regarding the regulation and
function of the PI3K/Akt and MAPKs pathways in the
context of doxorubicin-induced apoptosis [5–8].
The PI3K/Akt signaling pathway is probably the best-
characterized and most prominent pathway with regard to the
transmission of anti-apoptotic signals in cell survival [9–12].
The mitogen-activated protein kinases (MAPKs), which include
the ERK1/2, JNK, and p38 MAPK subgroups, are also known
to play fundamental roles in survival, proliferation, and
apoptosis [13]. A great deal of evidence has accumulated
suggesting that antitumor agents alter the activities of different
MAPK subgroups in a host of cancer cell lines [14].
Importantly, the pharmacological or molecular modulation of
MAPK signaling has been determined to influence apoptotic
responses to these anti-cancer drugs. However, the roles played
by MAPKs tend to be strongly dependent on context, and
profoundly influenced by cell type, drug concentration and
duration of exposure, and on the type of assay employed to
monitor apoptosis or cell survival [14]. In this study, we have
examined the regulation and function of PI3K/Akt and MAPKs
signaling pathways in doxorubicin-induced apoptosis in several
cell lines, and determined that the p38 MAPK and PI3K/Akt
pathways apparently exerts a regulatory effect with regard to the
induction of cell death and the sustained activation of ERK1/2
appears to be positively related to apoptosis. In particular, the
PI3K/Akt and ERK1/2 signaling pathways were determined to
be functionally involved in the regulation of doxorubicin-
induced apoptosis. Our results showed that Akt activation due
to overexpression of Myr-Akt apparently suppressed the
phosphorylation of ERK1/2 and ERK inactivation by over-
expression of ERK-DN had a negative effect on apoptosis.
Additionally, the positive relationship existing between sus-
tained ERK1/2 activation and DNA-damaging anticancer drug-
induced apoptosis was also observed in conjunction with the
etoposide-induced apoptosis. These findings indicate that the
Akt signaling pathway negatively regulates the activation of
ERK and that sustained ERK activation is positively involved in
the apoptosis. Collectively, our results underline the notion that
interplay between the Akt signaling pathway and the activation
of ERK plays a crucial role in the apoptosis induced by DNA-
damaging drugs, including doxorubicin and etoposide.2. Materials and methods
2.1. Cell culture, antibodies, and chemicals
Mouse embryo NIH3T3 fibroblasts and human HaCaT keratinocytes
were maintained in Dulbecco's Modified Eagle's Medium (DMEM)
supplemented with 10% fetal bovine serum (FBS) and antibiotics
(100 IU/ml penicillin, 50 μg/ml streptomycin) in a humidified 5% CO2
incubator, at 37 °C. Human A549 lung cancer and RKO colorectal
carcinoma cells were obtained from American Type Culture Collection and
cultured in RPMI 1640 medium supplemented with 10% FBS. Antibodies
against pro-caspase-3, actin, and cleaved poly(ADP-ribose) polymerase
(PARP), Akt, JNK, p38 MAPK, and phospho p38 MAPK were acquired
from Santa Cruz Biotechnology (Santa Cruz, CA), and the ERK1/2,
phospho-ERK1/2 (Thr-202/Tyr-204), phospho-JNK and phospho-Akt anti-
bodies used in this study were obtained from Cell Signaling Technology
(Beverly, USA). Doxorubicin, etoposide, and the specific kinase inhibitors,
PD98059, SB202190, SP600125, and LY294002 were purchased from
BioMol (Plymouth Meeting, PA, USA).
2.2. Flow cytometric analysis
The cells were trypsinized and collected via centrifugation at 1000×g
for 10 min. The harvested cells were then washed with PBS and
resuspended at a density of 1×106 cells/ml. For fixation, the cell
suspensions were maintained overnight at 4 °C, after the addition of
70% ethanol. The cells were then stained with PI solution (50 μg/ml
propidium iodide, 0.1% Triton X-100, 0.1 mM EDTA, and 50 μg/ml
RNase) for 20 min at 4 °C. The stained DNA was then analyzed via flow
cytometry (FACS Calibur; Beckton Dickinson). For the detection of PI, the
cells were excited at 488 nm, and their emissions were determined at a
range of wavelengths between 515 and 545 nm.
2.3. Immunoblot analysis
Cells in 100 mm dishes were washed three times with ice-cold PBS,
scraped from the dishes, and lysed in lysis buffer (100 mM Tris–HCl, pH
7.5, 10 mM NaCl, 10% glycerol, 1 mM Sodium orthovanadate, 50 mM
Sodium fluoride, 1 mM p-nitrophenyl phosphate, and 1 mM PMSF). The
lysates were then centrifuged for 15 min at 10,000×g, and the supernatants
were analyzed for protein concentration using a DC protein assay kit (Bio-
Rad Lab., CA, USA). Equal amounts of the proteins were separated on
polyacrylamide gels containing 0.1% SDS, and the resolved proteins were
transferred onto nitrocellulose membranes. The blots were stained with
Ponceau S. After a brief washing in TBS (20 mM Tris–HCl, pH 8.0,
137 mM NaCl) to destain the Ponceau S, the membranes were blocked for
1 h in Tris-buffered saline-Tween (TBST; 10 mM Tris–HCl, pH 7.5, 0.1 M
NaCl, and 0.1% Tween 20) containing 3% non-fat dry milk. The
membrane sheets were incubated with specific antibodies.
2.4. Cell viability assay
Cells were plated at a density of 5×104 cells in 96-well plates, and cell
viability was assessed via conventional MTT reduction assays. After incubation,
the cells were treated for 4 h with MTT solution (final concentration, 0.25 mg/
ml) at 37 °C. Dark blue formazan crystals forming in the intact cells were then
dissolved with Me2SO, and absorbance was measured at 570 nm using an
enzyme-linked immunosorbent assay reader. The results were then expressed as
percentages of MTT reduction, with the absorbance exhibited by the control
cells arbitrarily set to 100%.
2.5. Drug treatments
Cells in the exponential growth phase were seeded 1 day prior to the
experiments (2×105 cells per ml). The cells were incubated for 16 h in
drug-free medium and treated with either doxorubicin or etoposide for
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ubicin and other inhibitors, the cells were pre-incubated with the specific
kinase inhibitor, PD98059 (20 μM), SB202190 (20 μM), SP600125
(20 μM), or LY294002 (25 or 50 μM) for 1 h prior to the addition of
doxorubicin, and the same volumes of the corresponding solvents were
added to the controls.
2.6. Determination of the apoptotic nuclei by DAPI staining
We also conducted DAPI staining for the identification of apoptotic
nuclei. Cells were harvested at 2000 rpm for 5 min, washed once in cold
PBS, fixed in ice-cold methanol/acetic acid (1:1, v/v) for 5 min, and finally
stained with 0.8 mg/ml of 4′,6-diamidino-2-phenolindole (DAPI) in
darkness. Morphological changes in the apoptotic cells were visually
assessed under a Zeiss Axiovert 200 microscope, at the fluorescence DAPI
region (excitation, 351 nm; emission, 380 nm). To count the apoptotic
nuclei of the transiently transfected cells, the cells were co-transfected with
pEGFP (Clontech) and the indicated plasmids. After 48 h of transfection,
the cells were either left unexposed or exposed to the indicated agents. The
cells were fixed in 4% paraformaldehyde, and then stained with DAPI. The
numbers of cells harboring apoptotic nuclei among the GFP-expressing cells
were counted via fluorescence microscopy. Apoptotic cell death was then
calculated as the percentage of apoptotic cells over the total GFP-positive
cells [15,16].Fig. 1. Induction of cell death by doxorubicin in NIH3T3 fibroblasts. NIH3T3
cells were treated with different doses of doxorubicin for 24 h as indicated. Cells
treated with solution devoid of doxorubicin were used as controls (0). (A) Cell
viability was determined via MTT assay. The data are expressed as the means±
S.E. of values from three independent experiments. (B) The cells were harvested
and stained with propidium iodide, and their DNA contents were analyzed via
flow cytometry. (C) Poly(ADP-ribose) polymerase (PARP) is cleaved as the
result of caspase 3 activation in apoptotic cells after doxorubicin treatment. At
the indicated times, the cell lysates were separated via SDS-PAGE, and PARP
cleavage was analyzed via immunoblotting with mouse monoclonal antibody.
The blots were then re-probed with anti-actin antibody, in order to verify equal
protein loading.3. Results
3.1. Doxorubicin-induced apoptotic cell death in mouse
NIH3T3 fibroblasts
Doxorubicin, one of the best-known DNA-damaging
agents, is an antitumor agent administered as a treatment
for many different cancer types. The drug is used either
alone or in combination with other drugs for the treatment of
a variety of tumors, including malignant lymphomas and
leukemias. In order to investigate in more detail the
signaling pathways inherent to its apoptogenic effects in
the fibroblasts, we administered different amounts of
doxorubicin to murine NIH3T3 fibroblasts. As had been
expected, doxorubicin treatment resulted in a significant loss
of cell viability in the cells. At doxorubicin concentrations in
excess of 2 μM, the majority of the cells were dead after
24 h (Fig. 1A). This loss of cell viability occurred as the
result of apoptotic cell death, as was revealed by the results
of flow cytometry analysis, and the observed cleavage of the
caspase-3 substrate, PARP (Fig. 1B, C). We then elected to
employ 2 μM of doxorubicin in the subsequent experiments,
as this is also the initial plasma concentration utilized in
cancer patients undergoing doxorubicin chemotherapy.
At a concentration of 2 μM, doxorubicin was shown to
induce apoptotic cell death in the NIH3T3 cells, in a time-
dependent manner. Apoptosis was indicated by the accumu-
lation of a sub-G1 population, as well as the appearance of
DAPI-stained apoptotic nuclei in the NIH3T3 cells after the
administration of doxorubicin treatment (Fig. 2A). When
exposed to doxorubicin and incubated for 12 h, the
percentage of apoptotic cells in the samples evidenced a
marked increase (35.2%) as compared to the control (4.4%).
In order to determine whether these changes were attribu-
table to apoptotic changes, the nuclear morphology of thecells was assessed via fluorescence microscopy, using DAPI
staining. Nuclear condensation and fragmentation were
apparent upon exposure to doxorubicin (2 μM). Additionally,
doxorubicin appeared to induce the formation of an 89-kDa
PARP fragment, in a time-dependent manner (Fig. 2B). After
12 h of incubation with doxorubicin at the apoptotic
concentration (2 μM), cleaved PARP was readily detected.
However, the addition of the irreversible caspase-3 inhibitor
I, DEVD-CHO (DEVD), resulted in a marked inhibition of
this PARP cleavage (Fig. 2C).
Fig. 2. Doxorubicin-induced apoptosis of NIH3T3 fibroblasts. Cells (1×106
cells per ml) were cultured in the absence (control) or presence of 2 μM
doxorubicin for 12–24 h. (A) The cells were harvested and stained with
propidium iodide or DAPI, and their DNA content was analyzed by flow
cytometry or fluorescence microscopy, respectively. The percentage of apoptotic
cells was assessed by counting the cells with DNA contents below 2N. (B) At
the indicated times, the cell lysates were separated on SDS-PAGE, and the
proteins were analyzed via immunoblotting. (C) NIH3T3 cells were grown in
the absence or presence of doxorubicin or the caspase 3 inhibitor, DEVD-CHO
(2 μM). Very similar results were obtained from three independent experiments.
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in doxorubicin-treated NIH3T3 fibroblasts
Next, in order to characterize the doxorubicin-induced
changes in the kinase signaling pathways, we analyzed the
phosphorylation status of Akt and MAPKs during the
doxorubicin-induced apoptosis of the NIH3T3 fibroblasts. As
doxorubicin was reported to activate Akt in NCI-H522 humanlung adenocarcinoma cells [17], we then attempted to determine
whether doxorubicin activates Akt in the NIH3T3 fibroblasts. A
significant degree of Akt activation was detected via Western
blotting using a phosphospecific Akt (Ser473) antibody (Fig.
3A). Maximal increases in Akt phosphorylation occurred after
2 h, after which the levels of phosphorylation declined gradually
to basal levels. This decline in Akt phosphorylation was
coincident with the onset of PARP cleavage, which may mark
the onset of apoptosis. This finding, then, shows that a PI3K/
Akt-dependent pathway may be responsible for the doxorubi-
cin-induced increases in Akt phosphorylation, which have also
been observed to occur in NIH3T3 cells.
JNK is activated by treatment with several different anti-
cancer drugs. However, its role in doxorubicin-induced
apoptosis remains somewhat unclear. Therefore, we have
attempted to determine the effects of JNK phosphorylation in
doxorubicin-induced apoptosis in NIH3T3 cells (Fig. 3B). Our
findings indicate that JNK was activated by doxorubicin
treatment after 8 h, after which a substantial increase in the
activation of JNK was detected. Then, changes in ERK1/2
activation were monitored via Western blotting, using a
phospho-specific ERK1/2 (Thr202/Tyr204) antibody. Interest-
ingly, the treatment of NIH3T3 cells with 2 μM of doxorubicin
resulted in marked increases in the phosphorylation (Thr202/
Tyr204) status of ERK1 (44 kDa) and ERK2 (42 kDa) (Fig. 3C).
Maximal increases in ERK1/2 phosphorylation were observed
after 12 h, after which phosphorylation levels declined
gradually. The levels of activation of p38 MAPK in the
NIH3T3 cells were also determined using a phospho-specific
p38 MAPK (Tyr182) antibody. Maximal increases in p38
MAPK phosphorylation were detected after 2 h, a result
comparable to that seen with Akt phosphorylation (Fig. 3D).
After 2 h, the phosphorylation levels declined gradually towards
basal levels. In addition, the decrease in the phosphorylation of
p38 MAPK coincided with the onset of PARP cleavage, which
may constitute a marker for the onset of apoptosis. As, in certain
cases, the late induction of the MAPKs has been reported to
require de novo protein synthesis [3], we attempted to evaluate
the possibility that the induction of the Akt or MAPKs by
doxorubicin might be dependent on de novo protein synthesis.
We treated the cells with doxorubicin in the presence of the
protein synthesis inhibitor, cycloheximide, and found that
cycloheximide exerted no significant effects on the phosphory-
lation of ERK1/2, p38 MAPK, JNK, or Akt, thereby indicating
that the activation of Akt or MAPKs subsequent to doxorubicin
treatment requires no de novo protein synthesis (Fig. 3E). These
findings strongly suggest the interesting notion that reductions
in p38 MAPK phosphorylation and increases in ERK1/2 and
JNK phosphorylation may both be involved in the doxorubicin-
induced apoptosis of NIH3T3 cells.
3.3. Interplay between PI3K/Akt and MAPKs in
doxorubicin-induced apoptosis
MAPKs and PI3K/Akt signaling pathways are clearly
involved in a variety of cellular functions, including cell
growth, differentiation, development, and apoptosis. In order to
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pathways are functionally involved in the apoptotic effects of
doxorubicin, we treated cells with several kinase inhibitors,including LY294002, PD98059, SB202190, and SP600125,
each of which effects the blockage of a specific MAPK or PI3K/
Akt pathway. Treatment with SB202190 (p38 MAPK inhibitor)
Fig. 4. Effects of specific kinase inhibitors on doxorubicin-induced apoptosis. (A) NIH3T3 cells were treated with a specific kinase inhibitor such as PD98059
(20 μM), SB202190 (20 μM), JNK inhibitor (SP600125) (20 μM), or LY294002 (50 μM) for 1 h and then treated for 24 h with doxorubicin (2 μM). Cell death was
analyzed via flow cytometry. The percentages of apoptotic cells are shown. Cells to which no drug treatment was administered were employed as a control. (B) The
cells were treated with doxorubicin (2 μM) for the indicated time periods in the absence or presence of either SB202190 (20 μM) or LY294002 (50 μM) for 1 h, then
analyzed by Western blotting with anti-PARP antibody. (C) The NIH3T3 cells were treated with doxorubicin (2 μM) for 12 h, either with or without pretreatment with
LY294002. The cell lysates were then analyzed via Western blotting, using antibodies against phosphorylated (pho-) or unphosphorylated MAPKs, as indicated. (D)
RKO colon or A549 lung cancer cells were treated with LY294002 (25 μM) for 1 h and then treated for 24 h with doxorubicin (2 μM). Equal amounts of cell lysates
were resolved via SDS-PAGE, and analyzed via Western blotting with anti-ERK, anti-phospho-ERK, anti-PARP, and anti-actin antibodies.
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increases in doxorubicin-induced apoptosis, but treatment
with PD98059 (MEK/ERK inhibitor) effected only a slight
inhibition of doxorubicin-induced apoptosis (Fig. 4A). PARP
cleavage consistently increased as the result of the administra-
tion of SB202190 (p38 MAPK inhibitor) or LY294002 (PI3K/
Akt inhibitor) (Fig. 4B). These results indicate that the
activations of Akt and p38 MAPK are functionally involved
in the negative regulation of doxorubicin-induced apoptosis in
NIH3T3 fibroblasts, whereas sustained ERK activation might
be positively related to apoptosis.
We then attempted to characterize the interplay occurring
between PI3K/Akt and MAPKs signaling pathways in theFig. 3. Doxorubicin-induced differential activation of Akt and MAPKs. Cells were ex
the cell lysates were resolved via SDS-PAGE. The phosphorylation status of Akt and
phospho-JNK, (C) anti-phospho-ERK1/2, or (D) anti-phospho-p38 MAPK specific a
membranes with antibodies for the detection of the respective unphosphorylated prote
Akt and MAPKs were assessed under doxorubicin treatment. The NIH3T3 cells were
(2 μM) for either 2 h (for Akt, p38 analysis) or 12 h (for JNK, ERK1/2 analysis). T
phosphorylated (pho-) or unphosphorylated Akt or MAPKs, as indicated.doxorubicin-induced apoptosis of NIH3T3 fibroblasts. The
phosphorylation status of the MAPKs was evaluated during
doxorubicin-induced apoptosis in either the presence or
absence of the PI3K/Akt pathway inhibitor, LY294002.
Doxorubicin-induced ERK1/2 activation was found to have
been significantly increased in the presence of LY294002,
whereas no remarkable changes were noted in the phosphory-
lation of p38 MAPK or JNK (Fig. 4C).
To understand the regulation and function of PI3K/Akt and
ERK in doxorubicin-induced apoptosis of cancer cell lines, we
treated the RKO colon cancer and A549 lung cancer cells with
specific kinase inhibitors. Like the case in NIH3T3 fibroblasts,
treatment with LY294002 (PI3K/Akt inhibitor) resulted in theposed to 2 μM doxorubicin for indicated time periods. The cells were lysed, and
MAPKs was analyzed via Western blotting with (A) anti-phospho-Akt, (B) anti-
ntibodies, as indicated. Equal protein loading was verified via the probing of the
ins. (E) The effects of inhibition of de novo protein synthesis on the activation of
treated with 1 mg/ml of cycloheximide for 1 h prior to exposure to doxorubicin
he cell lysates were then analyzed via Western blotting using antibodies against
Fig. 5. Interplay between PI3K/Akt and ERK on doxorubicin-induced apoptosis.
(A) NIH3T3 cells were transfected with constitutively activated Akt (Myr-Akt)
or the dominant negative mutant form of Akt (Akt-DN). The transfected cells
were treated for 24 h with doxorubicin (2 μM). Equal amounts of cell lysates
were analyzed via SDS-PAGE and Western blotting using anti-ERK, anti-
phospho-ERK, anti-PARP and anti-actin antibodies. (B) Cells were transfected
with wild-type ERK or the dominant negative mutant form of ERK (ERK-DN).
The transfected cells were treated for 24 h with doxorubicin (2 μM). Western
blotting was done using anti-Actin, anti-PARP, and anti-procaspase-3
antibodies.
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cancer cell lines (Fig. 4D). The phosphorylation status of ERK
was evaluated during doxorubicin-induced apoptosis in either
the presence or absence of the PI3K/Akt pathway inhibitor,
LY294002. Doxorubicin-induced ERK1/2 activation and PARP
cleavage were significantly increased in the presence of
LY294002 (Fig. 4D). Taken together, our results imply a
specific interplay between the PI3K/Akt signaling pathway and
the ERK signaling pathway in doxorubicin-induced apoptosis.
3.4. Interplay between PI3K/Akt and ERK in
doxorubicin-induced apoptosis
In order to confirm the interplay between Akt and ERK in
doxorubicin-induced apoptosis, we transfected NIH3T3 cells
with constitutively active mutant form of Akt, myristolylated
Akt (Myr-Akt) or with the kinase-inactive and dominant
negative Akt mutant, Akt-DN (K197M). Expression of Akt-
DN showed a positive effect on the doxorubicin-induced ERK1/2
activation and caspase activation, whereas Akt activation due to
the expression of Myr-Akt apparently suppressed the phosphor-
ylation of ERK1/2 and PARP cleavage (Fig. 5A). Next, to
confirm the involvement of ERK stimulation in doxorubicin-
induced apoptosis, we overexpressed the wild-type ERK or the
kinase-inactive and dominant negative ERK mutant, ERK-DN
(K52R). Suppression of ERK activation by overexpression of
ERK-DN was shown to significantly repress the apoptotic
functions of doxorubicin, but this was not seen in the cells
treated with wildtype ERK (Fig. 5B). These results suggest
strongly that the PI3K/Akt signaling pathway may negatively
regulate the ERK signaling pathway, and the interplay between
the PI3K/Akt signaling pathway and the activation of ERK1/2
may play an important role in doxorubicin-induced apoptosis.
3.5. Interplay between PI3K/Akt and ERK in etoposide-induced
apoptosis of HaCaT keratinocytes
We reported in a previous study that the differential
activation of ERK1/2 by flavonoids plays an important role in
the regulation of etoposide-induced apoptosis in human HaCaT
keratinocytes, and also suggested that sustained ERK1/2
activation might be positively involved in etoposide-induced
apoptosis[18]. Therefore, we attempted to determine whether
the possible interplay between PI3K/Akt and ERK1/2 might
also be relevant to etoposide-induced apoptosis. Etoposide,
another plant-derived DNA-damaging anticancer drug, has
been shown to induce apoptotic cell death in both a dose- and
time-dependent manner (Fig. 6A and B). After the administra-
tion of etoposide treatment, a significant increase in PARP
cleavage was noted at 8 h, which was consistent with the time-
dependent activation of caspase-3 (Fig. 6B). Consistent with
doxorubicin-induced apoptosis, we determined that Akt phos-
phorylation increased within 2 h after etoposide treatment, and
declined gradually towards basal levels, whereas ERK1/2
phosphorylation was observed immediately after Akt inactiva-
tion (Fig. 6C). As the activation of ERK1/2 by etoposide was
suppressed as the result of the addition of PD98059, both PARPcleavage and caspase-3 activation were apparently reduced,
although no significant changes in Akt phosphorylation were
detected (Fig. 6D). Collectively, our results appear to show that
the PI3K/Akt signaling pathway negatively regulates the
activation of ERK1/2 induced by DNA-damaging drugs such
as doxorubicin and etoposide, and the sustained activation of
ERK1/2 was positively involved with the apoptosis induced by
DNA-damaging drugs.
In conclusion, the interplay occurring between the PI3K/Akt
signaling pathway and ERK1/2 activation may play a funda-
mental role in the apoptosis induced by DNA-damaging drugs,
most notably doxorubicin and etoposide.
4. Discussion
Doxorubicin, one of the most potent and most frequently
employed anti-cancer drugs, exhibits a broad spectrum of
biological activity. Previous studies have shown that doxoru-
bicin induces apoptosis at low concentrations, but induces
necrosis at higher concentrations in several cancer cell
variants [19–21]. In this study, we have conducted an
investigation into the functions of the ERK1/2, p38 MAPK,
Fig. 6. Activation of PI3K/Akt or ERK signaling pathways in the etoposide-induced apoptosis. The human HaCaT keratinocytes were treated with the indicated
amounts of etoposide (10 μM). (A) Cell viability was determined via MTTassay. (B) The cleavage of PARP and pro-caspase-3 was analyzed via Western blotting with
mouse monoclonal antibodies. The blots were then re-probed with anti-actin antibody, in order to verify equal protein loading. (C) The cells were incubated with
etoposide (10 μM) for the indicated time periods, and the cell lysates were subjected to immunoblot analysis with anti-ERK1/2, anti-phospho-ERK1/2, anti-Akt and
anti-phospho Akt antibodies. (D) The effects of ERK suppression on the cleavage of PARP or pro-caspase-3 and Akt phosphorylation were evaluated. HaCaT
keratinocytes were exposed to etoposide (10 μM) for 24 h, either with or without PD98059 pretreatment. The cell lysates were then analyzed via Western blotting.
965E.-R. Lee et al. / Biochimica et Biophysica Acta 1763 (2006) 958–968JNK and PI3K/Akt pathways in the context of the mechan-
isms underlying the apoptogenic properties of important
chemotherapeutic DNA-damaging drugs, most notably dox-
orubicin and etoposide.
c-Jun N-terminal protein kinase (JNK) was originally
identified as two protein kinases, p46 JNK1 and p54 JNK2
[22], both of which specifically phosphorylate the transcrip-
tion factor, c-Jun, at the Ser 63 and Ser 73 of its N-terminal
transactivation domain [22,23]. JNK is activated by a host
of cytotoxic drugs, and this activation generally contributes
to the mediation of drug-induced cell death [24–27].
Although some reports have shown that JNK is activated
by doxorubicin [5,28], its role in the regulation of
doxorubicin-induced cell death remains unclear. Our data
indicated that both JNK1 and JNK2 were activated to a
slight degree by doxorubicin. The activation of JNK was a
relatively late event in the response of NIH3T3 cells to
chemotherapeutic drugs (Fig. 3). Although the activationpatterns of other signaling molecules were complex, the
maximum extent of JNK activation ranged between 4 and 5
fold over basal levels. However, the suppression of JNK
activity exerted only minimally significant effects on
doxorubicin-induced apoptosis (Fig. 4A). JNK activation in
response to doxorubicin administration was not associated
with PI3K/Akt phosphorylation (Fig. 4C). p38 MAPK has
been demonstrated to either stimulate or inhibit apoptosis in
various cell lines, in conjunction with a variety of stimuli
[6,29–34]. The reason for these contradictory roles of p38
MAPK remains somewhat unclear. The differential effects of
p38 MAPK on apoptosis in different cell types may be
attributable to the heterogeneity of the expression and/or
activation of various p38 kinase isoforms [24,35]. In our
series of experiments, p38 MAPK activity was transiently
increased in response to doxorubicin treatment, and then
decreased, a pattern similar to that observed with Akt
phosphorylation (Fig. 3). Also similar to Akt, the inhibition
966 E.-R. Lee et al. / Biochimica et Biophysica Acta 1763 (2006) 958–968of p38 MAPK activation by SB202190 resulted in elevated
levels of doxorubicin-induced apoptosis (Fig. 4), thereby
suggesting that p38 MAPK functions as a anti-apoptotic
molecule in the doxorubicin-induced apoptosis of NIH3T3
fibroblasts.
The activation of the ERK1/2 pathway is normally
associated with cell proliferation and survival. However,
recent studies have implied that ERK1/2 may exert a dual
effect on proliferation. It has been shown to stimulate
proliferation via the induction of cyclin D expression and,
hence, the activation of cell cycle kinases [36,37]. In addition,
ERK1/2 may both phosphorylate and inactivate the p27 cell
cycle inhibitor protein [38,39]. However, ERK1/2 has also
been demonstration to stimulate apoptosis in T-cells, via the
enhancement of Fas ligand expression, and has also been
shown to induce apoptosis in response to ceramide exposure,
via the prevention of the inactivation of BAD, a member of
the pro-apoptotic bcl-2 family [40,41]. Only a very limited
amount of study has been focused on the regulation and
function of ERK1/2 in doxorubicin-induced cell death
[5,7,28]. Doxorubicin has been determined to induce the
activation of ERK1/2 in neuroblastoma SKN-SH cells, and
ERK1/2 activation in the cells appears to play an important
role in the enhancement of apoptosis, as the suppression of
ERK1/2 has been shown to result in a decrease in
doxorubicin-induced apoptosis [7]. Our study consistently
demonstrated that doxorubicin also induces apoptosis with
sustained ERK1/2 activation, and the suppression of ERK by
PD98059 treatment or ERK-DN expression appears to exert a
significant effect on doxorubicin-induced cell death (Fig. 3, 4,
and 5). We also demonstrated that sustained ERK1/2
activation is involved in etoposide-induced apoptosis of
HaCaT keratinocytes (Fig. 6).
The function and regulation of Akt/PKB in the mediation
of apoptosis has been the focus of intensive research.
However, the exact mechanisms underlying the Akt-induced
prevention of apoptosis remain controversial. Recent studies
regarding the importance of the PI3K and Akt pathways on
the control of cell survival may explain, in part, why so many
oncoproteins, growth factors, and survival factors have
evolved mechanisms for the activation of PI3K and Akt.
The importance of the role of Akt in transformation and
cancer was underlined by the cloning of the AKT2 gene.
AKT2 has been frequently observed to be amplified and
overexpressed in cases of cancer in humans [42,43]. Thus far,
three Akt family members have been identified in mammals,
and have been designated as Akt1/PKBα, Akt2/PKBβ, and
Akt3/PKBα [44]. Several lines of evidence appear to suggest
that Akt may constitute a critical target for the discovery of
novel anticancer drugs. First, Akt has been shown to be at the
crossroads of several oncogenic and tumor suppressor
signaling networks. Secondly, the frequent deregulation of
many Akt signaling pathway components has been observed
in cases of cancer in humans. The results generated by a
number of studies have also revealed that the overexpression
and activation of Akt renders tumor cells resistant to
chemotherapeutic drugs and signaling molecule inhibitors,including Gleevec, Iressa, Herceptin, and retinoid acid [45–
49]. Despite the host of studies thus far conducted regarding
the regulation of Akt in response to treatment with anti-cancer
agents, the importance of the PI3K/Akt pathway in drug-
induced apoptosis, as well as the nature of the interaction
between Akt and MAPKs signaling pathways, remains to be
clearly characterized [8,50–52]. Several studies have demon-
strated increases in the activation of Akt in response to
treatment with daunorubicin [50], staurosporine, and etopo-
side [52], whereas the inactivation of Akt has also been
observed as the result of treatment with doxorubicin [8] and
topotecan [51]. In this study, we observed the transient
(persisting for less than 10 h) activation of Akt in response to
the administration of DNA-damaging anticancer agents,
namely doxorubicin and etoposide. After approximately
10 h, Akt phosphorylation levels returned to their basal
levels, and cell death commenced (Figs. 3 and 6). The
suppression of Akt activation accelerated and induced an
increase in doxorubicin-induced cell death (Fig. 4 and 5).
Interestingly, the inhibition of Akt activation resulted in a
dramatic increase in ERK1/2 phosphorylation. This suggests
that the activation of the ERK signaling pathway may be
regulated by the PI3K/Akt signaling pathway in doxorubicin-
induced apoptosis. Akt activation was determined to occur as
a transient response of the cells to an apoptotic stimulus, and
this phenomenon may constitute a self-defense mechanism,
which protects cells against apoptosis. An eventual reduction
in Akt phosphorylation may prove necessary for the induction
of apoptosis in these cells. The mechanisms regulating the
induction of Akt and MAPKs in response to treatment with
doxorubicin remains unclear, but the mechanisms that
regulate the induction of Akt are also apparently involved
in the activation of ERK. In this study, we also determined
that sustained ERK activation is associated with etoposide-
induced apoptosis in human HaCaT keratinocytes (Fig. 6).
The findings of this study are generally consistent with the
findings of studies involving T cells, Jurkat T cells, and
neutrophils treated with hydrogen peroxide or other oxidant
agents [53,54].
In conclusion, this study suggests that sustained ERK
activation might be associated intimately with the apoptosis
induced by DNA damaging-drugs, and might be negatively
regulated by the Akt signaling pathway, thereby underlining the
importance of the interplay occurring between the Akt signaling
pathway and ERK activation in apoptosis. Our findings
represent a significant step forward in our understanding of
the signal transduction pathways associated with the apoptosis
elicited as the result of exposure to DNA-damaging anticancer
agents.
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